Tech Company Financing Transactions
Ractigen Therapeutics Funding Round
IDG Capital Partners participated in a $31 million funding round for Ractigen Therapeutics. The round closed on 7/30/2026.
Transaction Overview
Company Name
Announced On
7/30/2026
Transaction Type
Venture Equity
Amount
$31,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the clinical development of its saRNA assets, including advancing Phase 2 clinical trials for RAG-01 in non-muscle-invasive bladder cancer (NMIBC), preparing IND filing for RAG-18 in Duchenne muscular dystrophy (DMD), advancing Phase 2 clinical trials for RAG-17 in amyotrophic lateral sclerosis (ALS), and expanding its proprietary extrahepatic delivery platforms (SCAD and LiCO).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
32nd floor, 168 Yangshupu Rd., Hongkou Dist.
Shanghai, 200082
China
Shanghai, 200082
China
Phone
Website
Email Address
Overview
Our Vision: Improve Human Health by Innovation. Our Mission: Unleash the power of oligonucleotide therapeutics to tackle unmet medical needs. Ractigen Therapeutics, a clinical-stage pharmaceutical company, specializes in developing pioneering therapies aimed at enhancing the expression of therapeutic genes within diseased cells.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/30/2026: Bloom Security venture capital transaction
Next: 7/30/2026: Polar venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record all VC transactions involving tech companies. VC investment data records on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








